GlassScriptPhysician profile
Hagop Margossian
NPI 1952374571
$7,406.26
in general payments reported to CMS, 2019-2025
31 companies · $2,312 in 2025
The $2,312 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $561 · 2021: $552 · 2022: $404 · 2023: $631 · 2024: $1,266 · 2025: $2,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $934.00 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $687.69 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $659.10 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $641.04 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $595.96 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.55 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $450.72 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $400.00 | 2019 | |
| Amarin Pharma, INC. | $378.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $366.35 | 2023-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $361.99 | 2019-2025 | |
| Pfizer INC. | $286.45 | 2020-2025 | |
| Esperion Therapeutics, INC. | $133.37 | 2022-2025 | Nexletol |
| Abbott Laboratories | $131.76 | 2023-2025 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Cleerly, INC. | $127.07 | 2025 | Cleerly Ischemia, Cleerly Labs |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.20 | 2020-2022 | |
| Daiichi Sankyo INC. | $103.99 | 2019 | |
| Kestra Medical Technology Services, INC. | $84.97 | 2024-2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $74.33 | 2025 | Onpattro |
| Agepha Pharma Fz LLC | $70.11 | 2024-2025 | Lodoco |
| Medtronic, INC. | $49.91 | 2025 | Closurefast |
| Kiniksa Pharmaceuticals International, Plc | $47.65 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $45.49 | 2025 | Inspire |
| Bridgebio Pharma, INC. | $38.16 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $28.48 | 2025 | |
| Heartflow, INC. | $27.27 | 2025 | |
| Boston Scientific Corporation | $26.85 | 2025 | Varithena Administration Pack |
| Scpharmaceuticals INC. | $22.59 | 2024 | |
| Edwards Lifesciences Corporation | $22.28 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $21.00 | 2025 | Evkeeza |
| Azurity Pharmaceuticals, INC. | $19.27 | 2024 | Edarbyclor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hagop Margossian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.